Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Concomitant CALR and LNK mutations leading to essential thrombocythemia with erythrocytosis.

Luque Paz D, Boyer F, Beucher A, Bouvier A, Jouanneau-Courville R, Guardiola P, Lambert D, Delneste Y, Hunault M, Blanchet O, Ugo V.

Blood Cells Mol Dis. 2018 Jul;71:75-76. doi: 10.1016/j.bcmd.2018.04.002. Epub 2018 Apr 23. No abstract available.

PMID:
29703677
2.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Mar 6;123(10):1544-51. doi: 10.1182/blood-2013-11-539098. Epub 2013 Dec 23.

3.

Who to screen for calreticulin mutations? An audit of real-life practice and review of current evidence.

Haslam K, Langabeer SE.

Eur J Intern Med. 2017 May;40:e22-e23. doi: 10.1016/j.ejim.2017.01.020. Epub 2017 Jan 26. Review. No abstract available.

PMID:
28132789
5.

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A, Vannucchi AM; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Mar 6;123(10):1552-5. doi: 10.1182/blood-2013-11-538983. Epub 2013 Dec 26.

PMID:
24371211
6.

JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.

Wang J, Zhang B, Chen B, Zhou RF, Zhang QG, Li J, Yang YG, Zhou M, Shao XY, Xu Y, Xu XH, Ouyang J, Xu J, Ye Q.

Hematology. 2017 Apr;22(3):145-148. doi: 10.1080/10245332.2016.1252003. Epub 2016 Nov 22.

PMID:
27875935
7.

Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.

Kang MG, Choi HW, Lee JH, Choi YJ, Choi HJ, Shin JH, Suh SP, Szardenings M, Kim HR, Shin MG.

Oncotarget. 2016 Aug 30;7(35):57036-57049. doi: 10.18632/oncotarget.10958.

8.

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.

Rumi E, Harutyunyan AS, Pietra D, Milosevic JD, Casetti IC, Bellini M, Them NC, Cavalloni C, Ferretti VV, Milanesi C, Berg T, Sant'Antonio E, Boveri E, Pascutto C, Astori C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Apr 10;123(15):2416-9. doi: 10.1182/blood-2014-01-550434. Epub 2014 Feb 19.

PMID:
24553179
9.

Somatic mutations of calreticulin in myeloproliferative neoplasms.

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R.

N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.

10.

Essential Thrombocythemia Associated With Germline JAK2 G571S Variant and Somatic CALR Type 1 Mutation.

Panovska-Stavridis I, Eftimov A, Ivanovski M, Pivkova-Veljanovska A, Cevreska L, Hermouet S, Dimovski AJ.

Clin Lymphoma Myeloma Leuk. 2016 May;16(5):e55-7. doi: 10.1016/j.clml.2016.02.039. Epub 2016 Feb 27. No abstract available.

PMID:
27009537
11.

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.

Andrikovics H, Krahling T, Balassa K, Halm G, Bors A, Koszarska M, Batai A, Dolgos J, Csomor J, Egyed M, Sipos A, Remenyi P, Tordai A, Masszi T.

Haematologica. 2014 Jul;99(7):1184-90. doi: 10.3324/haematol.2014.107482. Epub 2014 Jun 3.

12.

Presence of calreticulin mutations in JAK2-negative polycythemia vera.

Broséus J, Park JH, Carillo S, Hermouet S, Girodon F.

Blood. 2014 Dec 18;124(26):3964-6. doi: 10.1182/blood-2014-06-583161. Epub 2014 Oct 10.

PMID:
25305205
13.

Diversities of Calreticulin Gene Mutations in Macedonian Patients With Essential Thrombocythemia.

Panovska-Stavridis I, Eftimov A, Ivanovski M, Stojanovic A, Georgievski B, Cevreska L, Dimovski AJ.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):477-81. doi: 10.1016/j.clml.2016.04.019. Epub 2016 May 6.

PMID:
27521277
14.

Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.

Daitoku S, Takenaka K, Yamauchi T, Yurino A, Jinnouchi F, Nunomura T, Eto T, Kamimura T, Higuchi M, Harada N, Saito N, Miyamoto T, Iwasaki H, Akashi K.

Exp Hematol. 2016 Sep;44(9):817-825.e3. doi: 10.1016/j.exphem.2016.05.001. Epub 2016 May 13.

PMID:
27185380
15.

CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.

Trifa AP, Popp RA, Cucuianu A, Bănescu C, Tevet M, Martin B, Murat M, Vesa SC, Dima D, Cândea M, Militaru MS, Pop IV.

Br J Haematol. 2015 Jan;168(1):151-3. doi: 10.1111/bjh.13076. Epub 2014 Aug 8. No abstract available.

PMID:
25103987
16.

Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.

Lim KH, Chen CG, Chang YC, Chiang YH, Kao CW, Wang WT, Chang CY, Huang L, Lin CS, Cheng CC, Cheng HI, Su NW, Lin J, Chang YF, Chang MC, Hsieh RK, Lin HC, Kuo YY.

Oncotarget. 2017 May 16;8(20):32476-32491. doi: 10.18632/oncotarget.16381.

17.

Two faces of ET: CALR and JAK2.

Chao MP, Gotlib J.

Blood. 2014 Mar 6;123(10):1438-40. doi: 10.1182/blood-2014-01-547596.

PMID:
24627549
18.

Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.

Rabade N, Subramanian PG, Kodgule R, Raval G, Joshi S, Chaudhary S, Mascarenhas R, Tembhare P, Gujral S, Patkar N.

Indian J Pathol Microbiol. 2018 Apr-Jun;61(2):209-213. doi: 10.4103/IJPM.IJPM_223_17.

19.

No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation.

Gau JP, Chen CC, Chou YS, Liu CJ, Yu YB, Hsiao LT, Liu JH, Hsu HC, Chiou TJ, Chen PM, Tzeng CH.

Blood Cells Mol Dis. 2015 Jun;55(1):36-9. doi: 10.1016/j.bcmd.2015.03.009. Epub 2015 Mar 30.

PMID:
25976465
20.

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.

Al Assaf C, Van Obbergh F, Billiet J, Lierman E, Devos T, Graux C, Hervent AS, Emmerechts J, Tousseyn T, De Paepe P, Papadopoulos P, Michaux L, Vandenberghe P.

Haematologica. 2015 Jul;100(7):893-7. doi: 10.3324/haematol.2014.118299. Epub 2015 May 1.

Supplemental Content

Support Center